Thank you
@helli, it's still as useful today after 2+ yrs with CGM as it would have been if someone were to have explained all that on day 1 with CGM! I found the Abbott series of short videos useful to introduce the basics of L2, but inevitably not spelling out the limitations! I didn't find the Dexcom material as good.
Libre 2 and my body turned out to not be good friends and as well as lots of L2 failures I was rarely getting interstitial readings that were near actual BG. But the trend arrows justified persevering with L2 as major assistance to my daily BG management. I subsequently was moved to Dexcom One which was better for reliability but still not very accurate. I'm now self-funding Dexcom G7 as a personal trial and that (with one exception) is extremely good.
For those newish to CGM there is a different thread in this Pumping and Technology Section titled "What CGM do you use?" - link given below. This does provide helpful dialogue from regular CGM users about their CGM experiences
and could be useful after getting started on CGM and once feeling a bit more adventurous!
Just curous, what with the issues that libre seems prone to, and the choice with dexcom 1, how many people are using each?
forum.diabetes.org.uk
Also possibly useful to people newish to CGM or just diabetes are the NICE Guidelines that provide the "rules" [
from which GPs, Hospital Specialists and the relatively new (1 July 22) Integrated Care Boards (ICBs) that replaced Cost Centre Groups (CCGs)] for the diagnosis and care of T1 and T2 diabetes. They include guidance for when CGMs can/should be prescribed.
NG 17, for Type 1, last updated Aug 22:
The National Institute for Health and Care Excellence
https://www.nice.org.uk › ng17
Type 1 diabetes in adults: diagnosis and management | Guidance
NG 28, for Type 2, last updated June 22:
The National Institute for Health and Care Excellence
https://www.nice.org.uk › ng28
Type 2 diabetes in adults: management | Guidance
These were last reviewed in 2022 and have been progressively widenening the availability of CGM. NICE Guidelines are pretty strong regulation for the NHS, but they are not manadatory for ICBs to adopt all the guidelines if funding provision is not immediately available. Now, in Sep 23, my regional ICB has not yet fully implemented details of NG17; still under review apparently - even though some of the details are cost neutral (eg Dexcom G6 vs the newer G7). Presumably it is the wider potential availability across the ICB that is causing an overall cost increase, which needs funding review.
Anyway, some of this is drifting away from the useful easy-read "limitations of CGM".